Skip to main content
# Table 1 Clinical features of patients with FCD IIb and TSC

Case no. | Gender | Age at surgery | Diagnosis | Seizure focus | Epilepsy duration (year) | Seizure frequency (per month) | Engel’s class | Application in the present study |
---|---|---|---|---|---|---|---|---|

1 | F | 7 | FCD IIb | F | 5 | 45 | I | qPCR, WB, IHC, |

2 | F | 1.8 | FCD IIb | F | 1.2 | 105 | II | ELISA |

3 | M | 3.5 | FCD IIb | T | 3 | 65 | I | qPCR, WB, IHC, |

4 | F | 7.5 | FCD IIb | F | 6.5 | 30 | I | qPCR, WB, IHC, |

5 | M | 5 | FCD IIb | T | 4 | 80 | II | ELISA |

6 | M | 4.3 | FCD IIb | O | 3.5 | 120 | I | qPCR, WB, IHC, |

7 | F | 9.5 | FCD IIb | P | 8 | 25 | I | ELISIA |

8 | F | 5.5 | FCD IIb | F | 4 | 60 | I | qPCR, WB, IHC, |

9 | M | 6 | FCD IIb | P | 4.5 | 35 | III | qPCR, WB, IHC, |

10 | F | 2 | FCD IIb | T | 1 | 55 | I | qPCR, WB, IHC, |

11 | M | 2.3 | FCD IIb | O | 1.3 | 70 | I | qPCR, WB, IHC, |

12 | F | 7 | FCD IIb | T | 5.5 | 30 | III | ELISA |

13 | F | 6 | TSC | P | 4.8 | 60 | I | qPCR, WB, IHC, |

14 | M | 2.1 | TSC | P | 1.2 | 110 | I | qPCR, WB, IHC, |

15 | M | 3.9 | TSC | T | 3 | 82 | I | qPCR, WB, IHC, |

16 | F | 7 | TSC | F | 5.6 | 26 | II | ELISA |

17 | F | 5.5 | TSC | T | 4 | 48 | I | ELISA |

18 | F | 4.8 | TSC | P | 3.8 | 75 | I | qPCR, WB, IHC, |

19 | M | 10 | TSC | T | 8.1 | 30 | I | qPCR, WB, IHC, |

20 | F | 6 | TSC | F | 4.5 | 25 | III | ELISIA |

21 | M | 5.5 | TSC | F | 4 | 31 | I | qPCR, WB, IHC, |

22 | M | 3 | TSC | T | 2.3 | 55 | I | qPCR, WB, IHC, |

23 | M | 1.5 | TSC | O | 0.9 | 100 | III | qPCR, WB, IHC, |

24 | F | 4 | TSC | P | 2.9 | 50 | I | qPCR, WB, IHC, |

25 | F | 3.5 | TSC | F | 2.6 | 45 | II | ELISA |